ES2654340T3 - Marcadores para cáncer endometrial - Google Patents

Marcadores para cáncer endometrial Download PDF

Info

Publication number
ES2654340T3
ES2654340T3 ES14183077.8T ES14183077T ES2654340T3 ES 2654340 T3 ES2654340 T3 ES 2654340T3 ES 14183077 T ES14183077 T ES 14183077T ES 2654340 T3 ES2654340 T3 ES 2654340T3
Authority
ES
Spain
Prior art keywords
endometrial cancer
markers
level
ikbke
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14183077.8T
Other languages
English (en)
Inventor
Miguel Abal Posada
Andreas Doll
Antonio Gil Moreno
Tamara Maes
Cristina Perez
Jaume REVENTÓS PUIGJANER
Elisabet Rosell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geadic Biotec AIE
Original Assignee
Geadic Biotec AIE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geadic Biotec AIE filed Critical Geadic Biotec AIE
Application granted granted Critical
Publication of ES2654340T3 publication Critical patent/ES2654340T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

Un procedimiento de diagnóstico in vitro para el diagnóstico de cáncer endometrial que comprende detectar el nivel del biomarcador IKBKE en una muestra de una paciente en el que un incremento en el nivel de IKBKE en comparación con un valor control indica la existencia de cáncer endometrial
ES14183077.8T 2009-07-24 2010-07-23 Marcadores para cáncer endometrial Active ES2654340T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09166398 2009-07-24
EP09166398 2009-07-24

Publications (1)

Publication Number Publication Date
ES2654340T3 true ES2654340T3 (es) 2018-02-13

Family

ID=42751506

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10736990.2T Active ES2523683T3 (es) 2009-07-24 2010-07-23 Marcadores para cáncer endometrial
ES14183077.8T Active ES2654340T3 (es) 2009-07-24 2010-07-23 Marcadores para cáncer endometrial

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES10736990.2T Active ES2523683T3 (es) 2009-07-24 2010-07-23 Marcadores para cáncer endometrial

Country Status (17)

Country Link
US (2) US9046522B2 (es)
EP (2) EP2848700B1 (es)
JP (1) JP5934093B2 (es)
KR (1) KR101828290B1 (es)
CN (2) CN105132529A (es)
AU (1) AU2010275699B2 (es)
BR (1) BR112012001469B1 (es)
CA (1) CA2767914C (es)
DK (1) DK2456889T3 (es)
ES (2) ES2523683T3 (es)
HR (1) HRP20141062T1 (es)
IN (1) IN2012DN00707A (es)
MX (1) MX2012000921A (es)
PL (1) PL2456889T3 (es)
PT (1) PT2456889E (es)
RU (1) RU2596394C2 (es)
WO (1) WO2011009637A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010275699B2 (en) * 2009-07-24 2016-06-16 Geadic Biotec, Aie. Markers for endometrial cancer
EP3249399A1 (en) * 2011-09-22 2017-11-29 Memorial Sloan-Kettering Cancer Center Detecting ovarian cancer
EP2787350A1 (en) * 2013-04-05 2014-10-08 Atlas Antibodies AB ASRGL1 in endometrial cancer
KR102113310B1 (ko) * 2013-09-03 2020-05-20 아주대학교 산학협력단 암 세포 분리용 조성물, 키트 및 이를 이용한 분리 방법
BR112017002888A2 (pt) 2014-08-12 2017-12-05 Nextgen Jane Inc sistema e método para monitoramento de saúde em fluido corpóreo coletado
US10435472B2 (en) * 2014-09-17 2019-10-08 Merck Patent Gmbh Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
CN107102141A (zh) * 2016-02-23 2017-08-29 中国科学院生物物理研究所 分子标记物cd71及在子宫内膜癌诊断、分期及预后中的应用
EP3442706A4 (en) 2016-04-13 2020-02-19 NextGen Jane, Inc. SAMPLE COLLECTION AND PRESERVATION DEVICES, SYSTEMS AND METHODS
US20190137499A1 (en) * 2016-05-04 2019-05-09 Fundació Hospital Universitari Vall D'h'ebron-Institut De Recerca Markers of Endometrial Cancer
GB201702392D0 (en) * 2017-02-14 2017-03-29 Univ Edinburgh Methods for cancer diagnosis using a gene expression signature
CN108732349A (zh) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 Lta4h作为指示肝内结节及早期预警肝癌的生物标志物
CN108732351A (zh) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 Eps8l2作为指示肝内结节及早期预警肝癌的生物标志物
CN108732350A (zh) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 Pla2g6作为指示肝内结节及早期预警肝癌的生物标志物
CN109085359A (zh) * 2017-06-13 2018-12-25 中国医学科学院肿瘤医院 血清蛋白标志物组合在结直肠癌筛查和诊治中的应用
CA3070041A1 (en) * 2017-07-21 2019-01-24 Fundacio Hospital Universitari Vall D'hebron-Institut De Recerca Ctnb1 as a marker for endometrial cancer
CN109097462B (zh) * 2018-09-10 2022-01-11 青岛市海慈医疗集团 Ap1m2基因作为诊断青光眼的分子标志物的应用
WO2020130190A1 (ko) * 2018-12-20 2020-06-25 경상대학교병원 신장암의 발병 위험성 예측 또는 진단을 위한 정보제공방법
CN109797217A (zh) * 2019-03-27 2019-05-24 河北医科大学第二医院 帕金森生物标志物及其在制备检测产品中的应用
CN109811058B (zh) * 2019-03-31 2021-11-12 青岛泱深生物医药有限公司 与宫颈疾病发生发展相关的生物标志物及其应用
WO2022226381A1 (en) * 2021-04-22 2022-10-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Diagnostic to support clinical trial matching and exploratory biomarker analyses in cancer patients
CN114317750A (zh) * 2021-12-29 2022-04-12 上海市第十人民医院 一种卵巢癌生物标志物及其在制备用于卵巢癌腹水转移疾病的药物或试剂盒中的应用
KR102584898B1 (ko) * 2022-10-24 2023-10-04 연세대학교 산학협력단 자궁내막암 진단 방법 및 이를 이용한 키트

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AUPO573697A0 (en) * 1997-03-20 1997-04-10 Prince Henry's Institute Of Medical Research Diagnosis of endometrial cancer
US7014996B1 (en) * 1998-10-02 2006-03-21 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
AUPQ219799A0 (en) 1999-08-13 1999-09-02 R. Lurie Pty Ltd Apparatus for obtaining potological samples
US6884578B2 (en) * 2000-03-31 2005-04-26 Affymetrix, Inc. Genes differentially expressed in secretory versus proliferative endometrium
RU2232397C2 (ru) * 2002-04-03 2004-07-10 НИИ онкологии им. проф. Н.Н. Петрова Способ ранней диагностики патологических состояний эндометрия
WO2004005891A2 (en) * 2002-07-10 2004-01-15 The Regents Of The University Of Michigan Expression profile of lung cancer
US7640114B2 (en) * 2003-05-21 2009-12-29 The Wistar Institute Of Anatomy & Biology Method of diagnosis of cancer based on gene expression profiles in cells
WO2005035746A2 (en) * 2003-10-02 2005-04-21 Xantos Biomedicine Ag Medical use of tbk-1 or of inhibitors thereof
JP5629894B2 (ja) 2004-12-07 2014-11-26 国立大学法人大阪大学 甲状腺乳頭癌を診断するための新規のマーカー
WO2006085684A2 (en) 2005-02-10 2006-08-17 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
CA2621057A1 (en) 2005-09-07 2007-03-15 Laboratoires Serono S.A. Ikk inhibitors for the treatment of endometriosis
US20070134687A1 (en) * 2005-09-12 2007-06-14 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing cancer
KR20080114689A (ko) * 2006-02-09 2008-12-31 유니버시티 오브 사우스 플로리다 증가된 ｂｃｌ-2에 의한 암의 발견
US20070287158A1 (en) * 2006-06-09 2007-12-13 George Gorodeski Cell collection and disease screening
EP1978106A1 (en) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
WO2008137591A2 (en) * 2007-05-02 2008-11-13 Biocept, Inc. Non-invasive detection of endometrial cancer
JP5419195B2 (ja) 2007-08-03 2014-02-19 国立大学法人愛媛大学 頭頸部癌の腫瘍マーカー
WO2009021338A1 (en) * 2007-08-15 2009-02-19 UNIVERSITé DE SHERBROOKE Alternative splicing gene variants in cancer detection
US8053198B2 (en) * 2007-09-14 2011-11-08 Meso Scale Technologies, Llc Diagnostic methods
WO2009126969A2 (en) * 2008-04-11 2009-10-15 Expression Pathology Inc. Biomarkers for endometrial disease
AU2010275699B2 (en) * 2009-07-24 2016-06-16 Geadic Biotec, Aie. Markers for endometrial cancer

Also Published As

Publication number Publication date
EP2456889B1 (en) 2014-09-03
WO2011009637A3 (en) 2011-04-14
JP2013500001A (ja) 2013-01-07
CA2767914A1 (en) 2011-01-27
US9046522B2 (en) 2015-06-02
CN105132529A (zh) 2015-12-09
MX2012000921A (es) 2012-06-12
KR20120047334A (ko) 2012-05-11
HRP20141062T1 (hr) 2015-01-02
PL2456889T3 (pl) 2015-02-27
BR112012001469A2 (pt) 2020-08-11
KR101828290B1 (ko) 2018-02-12
EP2848700A1 (en) 2015-03-18
US20150337392A1 (en) 2015-11-26
BR112012001469B1 (pt) 2021-08-10
WO2011009637A2 (en) 2011-01-27
CA2767914C (en) 2020-02-25
IN2012DN00707A (es) 2015-06-19
JP5934093B2 (ja) 2016-06-15
ES2523683T3 (es) 2014-11-28
PT2456889E (pt) 2014-11-21
CN102549169B (zh) 2016-02-24
EP2848700B1 (en) 2017-10-04
DK2456889T3 (en) 2014-12-01
RU2596394C2 (ru) 2016-09-10
US20120122726A1 (en) 2012-05-17
EP2456889A2 (en) 2012-05-30
CN102549169A (zh) 2012-07-04
AU2010275699B2 (en) 2016-06-16
AU2010275699A1 (en) 2012-02-02
RU2012106432A (ru) 2013-08-27

Similar Documents

Publication Publication Date Title
ES2654340T3 (es) Marcadores para cáncer endometrial
BR112013011072A2 (pt) receptor alfa de folato como um marcador de dianóstico e prognóstico para cânceres que expressam receptor alfa de folato
ES2721424T3 (es) Método de diagnóstico del cáncer de vejiga
EP2464753A4 (en) BIO RECOGNITION METHOD AND COMPOSITIONS
MX343363B (es) Metodos para recelularizar un tejido o un organo para una transplantabilidad mejorada.
AR077026A1 (es) Marcadores de riesgo para enfermedades cardiovasculares
PT2477551T (pt) Método para medição de pelo menos uma propriedade dum tecido biológico
DE102009037921A8 (de) Tubus für Operationsmikroskop
IL225875A0 (en) A vaginal indicator for detecting biomarkers of good health
CO6541624A2 (es) Dispositivo de diagnóstico oral
IT1397673B1 (it) Provetta per analisi diagnostiche
FI20096093A0 (fi) Tyytyväisyysilmaisin
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
PT2576825T (pt) Métodos para avaliar a receptividade do endométrio de uma doente
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
DK3025782T3 (da) Diagnostisk testbånd til væskeprøver
FR2997292B1 (fr) Plaque de translation du calcaneum
BR112013031431A2 (pt) método para o diagnóstico da doença de gaucher
HK1174955A1 (en) Detecting pax2 for the diagnosis of breast cancer pax2
WO2014020444A3 (en) Methods and compositions for diagnosis and prognosis in breast cancer
ES2578160T3 (es) Procedimiento de diagnóstico de infecciones de sitio quirúrgico
ES2493069T3 (es) CYBP como marcador del cáncer de pulmón
ATE544398T1 (de) Druckindikator für medizinische druckverbände
MX343803B (es) Complejo de ipp como marcador para tratamiento de erlotinib.
BR112012023485A2 (pt) marcadores moleculares para infecções do trato urinário.